Virus News and Research

Latest Virus News and Research

'Core-shell' nanoparticles for effective intracellular delivery of RNAi therapeutics

Alnylam Pharmaceuticals, Inc., a leading RNAi therapeutics company, together with collaborators at the Massachusetts Institute of Technology (MIT), announced today the publication of new paper describing discovery of "core-shell" nanoparticles for systemic delivery of RNAi therapeutics.

26 Jul 2011

Book on human papilloma virus

A pair of oncologists in the Program in Women's Oncology at Women & Infants Hospital of Rhode Island recently co-authored a pocket-sized guide to the human papilloma virus (HPV) so physicians can make more accurate diagnosis and plan more effective treatment for women with the virus.

26 Jul 2011

Sediments buried beneath the Black Sea contain ancient virus and host DNA

A scientist analyzing ancient plankton DNA signatures in sediments of the Black Sea has found that the same genetic populations of a virus and its algal host can persist--and coexist--for centuries.

26 Jul 2011

Advaxis submits protocol revision for ADXS-HPV CIN Phase II study

Advaxis, Inc., a leader in developing the next generation of immunotherapies for cancer and infectious diseases, has submitted a protocol revision that has passed FDA review for the enrollment of the next 40 subject "mid strength" dose cohort in the dose-ranging Phase II study of ADXS-HPV, an immunotherapy for Cervical Intraepithelial Neoplasia.

26 Jul 2011

Nanoviricides lead anti-HIV candidate as good as HAART cocktail therapy

NanoViricides, Inc. reports that its lead anti-HIV candidate achieved anti-HIV efficacy equivalent to a HAART triple drug cocktail in its recently completed animal study.

25 Jul 2011

Tel Aviv University researcher tracks clinical cases of West Nile Virus

Since 1999, several outbreaks of West Nile Virus, which causes fever or severe neurological symptoms and is transmitted from birds to humans by blood-sucking mosquitoes, have been seen in the U.S., usually during the summer months. But researchers aren't certain how the virus migrated here - and they don't know how, or where, it will appear next.

25 Jul 2011

Janssen receives FDA Complete Response letter for SIMPONI sBLA to treat RA

Janssen Biotech, Inc. announced today that the U.S. Food and Drug Administration (FDA) issued a Complete Response letter for its supplemental Biologics License Application (sBLA) for SIMPONI.

25 Jul 2011

Hendra virus continues in Queensland

Experts have confirmed the eighth outbreak of the deadly Hendra virus in Queensland in a horse on the western Darling Downs. It is not known yet if a large number of people have been exposed to the sick animal, with passers-by and neighbours possibly having stroked it on the Chinchilla property where it lived as a pet.

24 Jul 2011

Effects of refusal and delay in childhood vaccination

Alison M. Buttenheim, PhD, MBA, assistant professor at Penn Nursing answers parents' questions about childhood vaccines. Dr. Buttenheim is a public health researcher and social demographer who studies parent behavior and child health.

22 Jul 2011

IDEXX Laboratories second quarter revenues increase 13% to $317.9 million

IDEXX Laboratories, Inc., today reported that revenues for the second quarter of 2011 increased 13% to $317.9 million, from $281.5 million for the second quarter of 2010. Organic revenue growth, as defined below, was 8%.

22 Jul 2011

IAS conference concludes with positive news on HIV prevention

"Scientists on Wednesday wrapped up their biggest forum in the 30-year history of AIDS, unveiling stunning weapons to prevent the spread of HIV," Agence France-Presse reports about the 6th International AIDS Society Conference on HIV Pathogenesis, Treatment and Prevention in Rome.

22 Jul 2011

Hepatitis B immunization for health care students may fall short of current recommendations

A study in the August issue of Infection Control and Hospital Epidemiology, the journal of the Society for Healthcare Epidemiology of America (SHEA), suggests that documentation of hepatitis B vaccination for health care students may fall short of current recommendations.

22 Jul 2011

HIV-infected MSM more likely to contract HCV through sex

Sexual transmission of hepatitis C virus (HCV) is considered rare. But a new study by researchers at Mount Sinai School of Medicine, working with the Centers for Disease Control and Prevention (CDC), provides substantial evidence that men with HIV who have sex with other men (MSM) are at increased risk for contracting HCV through sex.

22 Jul 2011

GIDAC recommends FDA approval of Janssen's REMICADE for treatment of pediatric UC

Janssen Biotech, Inc., formerly Centocor Ortho Biotech Inc., announced today that the Gastrointestinal Drugs Advisory Committee of the U.S. Food and Drug Administration recommended the approval of REMICADE for the treatment of moderately to severely active ulcerative colitis in pediatric patients who have had an inadequate response to conventional therapy.

22 Jul 2011

NIAID awards $36M grant to BIDMC for AIDS vaccine research in nonhuman primates

Beth Israel Deaconess Medical Center (BIDMC) has been awarded a grant from the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health, to lead a Consortium for AIDS Vaccine Research in Nonhuman Primates.

21 Jul 2011

Cell biologists identify infection mechanism of adenoviruses

Mucosal epithelia do not have any receptors on the outer membrane for the absorption of viruses like hepatitis C, herpes, the adenovirus or polio, and are thus well-protected against pathogenic germs. However, certain viruses, such as the human immunodeficiency virus HIV, still manage to enter the body via the mucous membrane.

21 Jul 2011

Boosted REYATAZ shows durable viral suppression in women with HIV

Bristol-Myers Squibb Company announced results from a long-term, retrospective, European cohort study, which included 1,294 antiretroviral (ARV)-experienced patients from Germany, France and Sweden, that were presented today at the Sixth International AIDS Society Conference on HIV Pathogenesis, Treatment and Prevention.

21 Jul 2011

Roche, Merck sign new non-exclusive agreement for HCV triple combination therapy

Merck, known as MSD outside the United States and Canada, announced today that it has signed a new non-exclusive agreement with Roche, through the companies' respective subsidiaries, for the global promotion, upon appropriate marketing approvals, of VICTRELIS (boceprevir) as part of a triple combination therapy regimen with peginterferon alfa and ribavirin.

21 Jul 2011

Final SVR results from Pharmasset's PSI-7977 phase 2b study in HCV

Pharmasset, Inc. announced today the final sustained virologic response (SVR) results from its phase 2b PROTON study with PSI-7977 dosed once daily in combination with peginterferon alfa 2a and ribavirin in subjects with hepatitis C virus (HCV) genotype 2 or 3 who have not been treated previously.

20 Jul 2011

IAS conference opens with push for treatment as prevention

The 6th International AIDS Society (IAS) Conference on HIV Pathogenesis, Treatment and Prevention taking place in Rome this week "started optimistically as the hype surrounding the use of antiretroviral treatment to prevent HIV infection gained momentum. But the focus of much discussion … will undoubtedly be on how to transform the recent promising research findings into workable policy," PlusNews reports.

20 Jul 2011